Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Phototherapy is the most frequently used treatment in neonatology when serum bilirubin levels exceed physiological limits. Light-emitting diodes (LEDs) are become routinely used for phototherapy in neonates with hyperbilirubinemia. Blue LED light with peak emission around 460 nm is regarded as the most suitable light sources for phototherapy and they recommended by most neonatal guidelines. However, the effectiveness of phototherapy with narrow-band LED light sources can be increased by expanding the spectral range of incident radiation within the absorption of bilirubin due to the strongly marked heterogeneity absorption properties of bilirubin in a different microenvironment. Longer wavelength light, such as green light, is expected to penetrate the infant's skin deeper. It is still controversial whether the use of green light has any advantage over blue light. The most effective and safest light source and the optimal method to evaluate phototherapy, however, remain unknown.The aim of this study was to compare, at equal light irradiance, the clinical efficacy of broad spectrum blue- green LED with blue narrow spectral band phototherapy device.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1.Blue-Green LED wide band phototherapy | Experimental | For experimental group was used "Malysh" phototherapeutic device (Luzar ltd, Belarus); it includes of eighteen blue- green super bright LEDs (12 blue (λmax 476 ) and 6 green (505 nm). |
|
| 2.Blue LED narrow band phototherapy | Active Comparator | For control group was used blue LED BILI-THERAPY (Atom Medical Inc., Tokyo, Japan) in high-mode which have a 20 μW/cm2 with peak wavelength between (λmax 480 nm). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Blue-Green LED photoherapy | Device | Continuous phototherapy for 24 h, for newborns placed incubators or radiant warmers will interrupted only for feeding and nursing for 20 - 30 min every three hours. |
| Measure | Description | Time Frame |
|---|---|---|
| Bilirubin level reduction | Reduction in TSB levels after phototherapy for 24 hours | 24 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Days of phototherapy | Duration of phototherapy | "Through study completion, an average of 1 month. |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse outcomes | Any adverse effects or patologycal symptoms during phototherapy | "Through study completion, an average of 1 month. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Pavel Mazmanyan, Prof | Contact | +37491416589 | pavelart@gmail.com | |
| Gohar Margaryan, MD | Contact | +37496023057 | goharmargaryan1991@mail.ru+ |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Erebouni Medical Centre, NICU | Recruiting | Yerevan | Armenia |
Not provided
| ID | Term |
|---|---|
| D051556 | Hyperbilirubinemia, Neonatal |
| D007567 | Jaundice, Neonatal |
| ID | Term |
|---|---|
| D007232 | Infant, Newborn, Diseases |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D006932 | Hyperbilirubinemia |
| D010335 | Pathologic Processes |
Not provided
Not provided
Prospective randomized controlled trial
Not provided
Not provided
no masking
|
| D013568 | Pathological Conditions, Signs and Symptoms |